ライフサイエンスコーパス: BTT

1 BTT was more cost-effective at $205 to $272/disability-a

2 BTT-1023 is a fully human monoclonal anti-VAP-1 antibody

3 BTT-VAD therapy is associated with improved survival and

4 y, in under flow conditions (90 dynes/cm(2)) BTT-3033, but not BTT-3034, inhibited collagen binding b

5 ased metal-organic framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate)

6 hange of the guest Mn2+ ions in Mn3[(Mn4Cl)3(BTT)8(CH3OH)10]2 (1-Mn2+; BTT=1,3,5-benzenetristetrazola

7 -) enables formation of [Mn(DMF)6]3[(Mn4Cl)3(BTT)8(H2O)12]2.42DMF.11H2O.20CH3OH, featuring a porous m

8 and 1,3,5-tris(2H-tetrazol-5-yl)benzene (H(3)BTT), promoted by a urea derivative, leads to a highly p

9 t ambient temperatures, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazola

10 Following implant, 82% (BTT) and 80% (DT) of patients at 6 months and 79% (DT) a

11 A BTT strategy is more effective and cost-effective than a

12 Thirteen patients received MARS as a BTT, of which 9 were transplanted with a 1-year survival

13 HTX recipients undergoing LVAD implant as a BTT.

14 In the model, a BTT strategy treating adults with a 10-year CVD event ri

15 Thus, the binding sites for BTT-3033 and BTT-3034 are differentially available in distinct integr

16 imilar sulfonamide derivatives, BTT-3033 and BTT-3034, and show that, under static conditions, they h

17 LVADs were implanted as BTT in 30 patients.

18 sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42

19 ntricular assist devices (LVAD) as a bridge (BTT) to heart transplantation (HTX) may be limited by th

20 framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate), featuring coordi

21 es, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazolate) series of framew

22 In static conditions BTT-3034, but not BTT-3033, inhibited collagen binding b

23 ganic framework Cr3 [(Cr4 Cl)3 (BTT)8 ]2 (Cr-BTT; BTT(3-) =1,3,5-benzenetristetrazolate), featuring c

24 red spectroscopy studies of Mn-, Fe-, and Cu-BTT, allowing the thermodynamics of H(2) adsorption to b

25 tructurally similar sulfonamide derivatives, BTT-3033 and BTT-3034, and show that, under static condi

26 -dicarboxylic acid bis-(2-butyloctyl) ester (BTT) and 4,8-bis(2-butyloctyl)benzo[1,2-b:4,5-b']dithiop

27 to evaluate survival benefits and costs for BTT-VAD versus nonbridged heart transplant recipients.

28 rovides poor discrimination of mortality for BTT patients and only modest discrimination for DT patie

29 ps for patients implanted for DT but not for BTT.

30 roups was 8%, 7%, and 16%, respectively, for BTT patients; 9%, 12%, and 19%, respectively, for DT pat

31 Thus, the binding sites for BTT-3033 and BTT-3034 are differentially available in di

32 Over a 20-year time horizon, BTT-VAD therapy increased survival at an increased cost

33 ly induced synovitis were imaged with (123)I-BTT-1023 SPECT/CT.

34 Clinical (124)I-BTT-1023 PET studies with injected radioactivity of 0.5-

35 estimated human effective dose due to (124)I-BTT-1023 was 0.55 mSv/MBq, if blockage of thyroid uptake

36 Human radiation dose estimates for (124)I-BTT-1023 were extrapolated.

37 nging from 0.54 to 0.58 for the HeartMate II BTT and DT groups, respectively.

38 ratures, the M(3)[(M(4)Cl)(3)(BTT)(8)](2) (M-BTT; BTT(3-) = 1,3,5-benzenetristetrazolate) series of f

39 line with results from previously reported M-BTT frameworks.

40 ns in Mn3[(Mn4Cl)3(BTT)8(CH3OH)10]2 (1-Mn2+; BTT=1,3,5-benzenetristetrazolate) with selected cations

41 In static conditions BTT-3034, but not BTT-3033, inhibited collagen binding by an alpha2 varian

42 onditions (90 dynes/cm(2)) BTT-3033, but not BTT-3034, inhibited collagen binding by an alpha2 varian

43 al, we elucidate how CO(2) binds to a novel "BTT-type" metal-organic framework (MOF) featuring open m

44 The action of BTT-3033, unlike that of BTT-3034, was dependent on Tyr-

45 ysis estimated a 59%, 54%, and 43% chance of BTT-VAD therapy being cost-effective for high-, medium-,

46 The comparative effectiveness of BTT was robust to uncertainties in CVD risk estimation a

47 The action of BTT-3033, unlike that of BTT-3034, was dependent on Tyr-285.

48 ng CHO cell adhesion to collagen I, but only BTT-3033 blocks platelet attachment under flow (90 dynes

49 Radioiodinated BTT-1023 cleared rapidly from blood circulation and dist

50 y, we preclinically evaluated radioiodinated BTT-1023 for inflammation imaging.

51 The radioiodinated BTT-1023 was able to detect mild inflammation in vivo.

52 e intravenously injected with radioiodinated BTT-1023.

53 Device [Thoratec Corporation]) for the same BTT indication in the same time period.

54 market approval, actual patient care setting BTT population support the original findings from the pi

55 In model-based analyses, a simple BTT strategy was more effective and cost-effective than

56 The BTT strategy recommended treatment to fewer people at hi

57 to variations in the age range analyzed, the BTT treatment threshold, or rates of treatment access, a

58 However, the superiority of the BTT strategy for averting microvascular complications is

59 ot change the comparative superiority of the BTT strategy, nor did titrating treatment using fasting

60 Compared with the TTT strategy, the BTT strategy would be expected to avert 24.4-30.5% more

61 ower risk of diabetes complications-than the BTT.

62 However, if insulin were unavailable, the BTT strategy would no longer be superior for preventing

63 only accepted willingness-to-pay thresholds, BTT-VAD therapy is likely to be cost-effective relative

64 g longer with MCSs for bridge to transplant (BTT) and destination therapy (DT).

65 Device in the ADVANCE bridge to transplant (BTT) trial and continued access protocol were reviewed.

66 California) LVAD as a bridge to transplant (BTT, n = 486) and DT (n = 638) and 114 DT patients with

67 nton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) tr

68 ALF patients as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or i

69 he HM II LVAD for bridge to transplantation (BTT).

70 ffectiveness of a bridge-to-transplantation (BTT)-VAD approach relative to direct heart transplantati

71 target, a benefit-based tailored treatment (BTT) strategy emphasizing lowering CVD risk, or a hybrid

72 ]), with a benefit-based tailored treatment (BTT) strategy, aiming to lower estimated risk for compli